is all in $AAPL $TSLA and $PMCB
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Because AXIM has only 52M shares outstanding. OWCP has around 140M.
We will see a bounce, once efficacy results drop, but to say it will react exactly like AXIM probably isn't accurate. On the other hand, AXIM just has the IBS gum while OWCP has a vast pipeline, licensing and consulting.
I bought some last month at .35 and I'm still long. I'm sitting on this one until 2018 frankly. I don't expect much to happen this year, but they are at the conference today so who knows what interest and attention that will bring.
Oh man I was going to buy more at $13+ this morning. I snoozed! I loosed!
March 2017
Safety study is on healthy people, efficacy study is on people with a variety of skin conditions. Two studies.
OWCP's 2017 PowerPoint estimated $2-4 Million a month in THREE years for the psoriasis cream, so I think they are being very conservative. But I will tell you from what I know about people with psoriasis- if something new comes to the market and it works well and it works fast, news will spread very quickly.
Do you know anyone who suffers from psoriasis?
IF OWCP is legally/ethically able to post any before/after photos from the ongoing IRB trials, news will spread so fast in the psoriasis community it will make your head spin. Otherwise, we'll have to wait a few months for people to post their own before/after photos. But news will spread very quickly. The real question is what will the price of the cream be.
If you look at OWCP's twitter feed you'll see a lot of psoriasis suffers and psoriasis awareness companies are already following OWCP. OWCP also recently setup an Instagram account. My bet this will be for before/after skin condition photos.
Word will spread fast about the cannabis-based psoriasis cream, because we all know how few side effects cannabis has.
My mother-in-law has been using a CBD cream for her rheumatoid arthritis. She loves it compared to the other medical creams/meds she had used. The only side effect for her is that if she uses too much of the cream it makes her a bit sleepy. You know what, she'll take sleepy over the many annoying side effects of all her previous topical and oral meds.
I'm not a chartist, but I do consult BarChart daily:
https://www.barchart.com/stocks/quotes/OWCP
Love to see the Bulls in control on $OWCP.
823K Bought / 395K Sold. Nice move up on low volume!
LIttle off topic but wanted to post here for my friends:
After Months of Public and Legal Pressure, DEA Removes Marijuana Misinformation from Website
https://thejointblog.com/dea-removes-marijuana-misinformation-website/
Welcome to the party my friend!
If they trade on a US exchange they are governed by the rules of that exchange.
You know this.
The comment you make about ISrael etc and pr's is not relevent.
I've had direct contact with them on a few occasions and the first thing I noticed is that English is not their first language. That turns off a lot of people, but English isn't my first language so I give people the benefit of the doubt.
Second, OWC is an Israeli sub of OWCP. From what I can glean, Israel has stricter laws regarding PR than the US does. So I think that has a lot to do with their overly cautious nature.
Frankly, it's good and bad. On the plus side for new investors, I believe it makes them undervalued. On the downside for existing investors, it makes them undervalued.
Don't mean to sound like a broken record here, but we have to look at the overall landscape with OWCP giving the Keynote address at the WSC on March 1st.
Does OWCP really want to go into that sort of event with share price below $1? Dunno. On the one hand, individual investors there would see the value and likely invest. On the other hand, most institutional investors won't touch stocks that trade for less than $5, let alone less than a buck.
What I do know is that OWCP could drop news at any time regarding the 3 State Consulting contracts AND they could drop news on final patent applications AND they could drop news on the licensing of their 2 ready-to-market delivery systems.
Bottom line, it's going to be a very interesting few weeks!
If you look at the pattern of 8-K filings, they are dropping positive news every few weeks.
We know from the 2017 PowerPoint that OWCP has signed 3 consulting contracts with MMJ States. Not with companies, with freaking States. We are expecting the terms of those agreements to be announced before March 1.
Yes, that article alone has converted people on the Reddit weedstocks board.
PharmaCyte’s management, Dr. Manuel Hidalgo, TD2 and TD2’s consulting statistician are actively working to finalize the number of patients that will be included in the trial. This is the final element and will complete the adjustments necessary for a newly designed trial.
https://finance.yahoo.com/news/pharmacyte-biotech-moves-closer-filing-140000370.html
Sounds like they are very close!
Just picked up some $M. Book value is over $40 on real estate alone. Dividend is 4.7%. I'm happy to get paid to hold this, betting that they will continue to push their business online and sell off brick-and-mortar locations. Of course, a buyout would be awesome.
"COSTA MESA, CA / ACCESSWIRE / February 13, 2017 / NEMUS Bioscience, Inc. (NMUS) announced that the company and its research and development partner, the University of Mississippi School of Pharmacy (UM), have conducted in vitro and in vivo bio-distribution and anti-addictive studies of NB2111, a unique analogue of cannabidiol (CBD). In the studies, NB2111 exhibited molecular stability in both gastric and intestinal pH modeling and did not convert to tetrahydrocannabinol (THC). We believe this is an important advantage over plant-derived CBD, which in these studies, partially converted to THC, the cannabinoid with psychoactive properties. Additionally, NB2111 exhibited an ability to penetrate all major organ systems, including the brain. Of note, the molecule showed a predilection for liver tissues that we believe might be exploited for the treatment of liver diseases responsive to cannabinoids. Lastly, NB2111 showed a statistically significant ability to mitigate opioid addiction in a validated animal model of addiction versus plant-derived CBD. This data complements the company's previously reported analgesic data related to NB2111 providing analgesia comparable to morphine."
http://finance.yahoo.com/news/nemus-bioscience-reports-favorable-bio-133000374.html
Great news! Doctors would certainly prescribe a med that had no psychoactive properties, over one that did, given a choice.
From what I've read, cannabinoids get converted by the liver, so for certain types of treatments it's desirable to go right to the bloodstream. Sounds like NB2111 is more stable than natural CBD in the liver, which could lead to novel liver treatments.
There is a huge need for non-addictive painkillers in the World. Very encouraging news.
Will change my username to Quad9!!!
How about triple 9s?!? $9.99 anyone!
IF you have a Reddit account, please consider posting on this thread in which someone asks why so many people on Reddit seem to dis the stock:
https://www.reddit.com/r/weedstocks/comments/5tpkcn/just_trying_to_understand_why_owcp/
Multiple revenue streams are going to be disclosed in Q2 and Q3 IMHO.
First, we have the 3 consulting contacts that were signed with US States. We know OWC was in the US and Canada recently, so perhaps there are more than 3 contracts by now.
International Consultancy
• Covering expertise with growers, breeds,
patients treatments, educational
programs, regulation and more.
• Signed 3 agreements to consult in the US.
Psoriasis (Skin Disease)
• Pharma-grade ‘challenge tests’ successfully completed
05/2016
• Safety study at Sheba, Tel Hashomer under approved
IRB (Helsinki) protocol. To be completed 3/2017
• In-vitro psoriasis efficacy study of the topical crème to
be completed by 3/2017
• IP owned by OWCP
• EXPECTED MARKET READINESS : Q2/2017
Cannabis Based Products
IP-owned developed of new innovative and tested delivery
systems.
• Two products ready to market:
• Sublingual Soluble tablet: replacement of smoking, pain
treatment. more than 10 million potential patients in the approved
MMJ states.
• Topical crème: Treatment for different skin diseases starting with
tested psoriasis. ~8 Million Psoriasis patients US & Canada (2.5% of
population), 3 years potential is 2-4 millions monthly income
(following current market prices)
• Fixed and controlled dosage
• Quality controlled
• Waiting for safety and clinical results
Clinical trials, patent applications, just about everything a pre-clinical biotech needs to do is more expensive in the US. Savvy, cost-conscious companies are realizing that they can get the ball rolling overseas and then file in the US afterwards.
Someone posted this earlier:
https://register.epo.org/smartSearch?searchMode=smart&query=one+world+cannabis
I seriously doubt that, but nice try pumping that stock. 7/10.
IF OWCP were to invest in another company it would be disclosed in an SEC filing. HOWEVER, it makes ZERO sense for OWCP to use any capital for speculation when it can be used for clinical trials.
I know, right, I seriously need a new hobby!
I was dozing off last night and I found myself in a supermarket checkout line. I glanced around and I see "CypCap" on the cover of Time magazine with the CiaB graphic.
http://www.trademarkia.com/cypcap-87054409.html
Spray would likely be taken several times a day as a preventative. I seriously doubt a doctor would ever recommend trying to get someone who was seizing to orally ingest a pill. Charlotte from the "Charlotte's Web" story currently takes drops I recall.
Witchcraft, got it!
Hey, can I borrow your crystal ball? : )
Technical Event
"Cara Therapeutics Inc Enters Wave 3 of Elliott Wave Cycle
02/09/2017
Recognia has detected that Cara Therapeutics Inc (CARA on NASDAQ) has entered Wave 3 of its Elliott Wave cycle. This bullish signal indicates that the price may rise from the previous close of 16.33 to the next Elliott Wave target price of 18.90.
Wave 3 of the Elliott Wave cycle is the third and typically the most powerful move in the five wave trend. This move is in the direction of the overall market trend (either bullish or bearish). By definition, Wave 3 cannot be the shortest of the three impulsive waves and should as a rule have greater volume then either Wave 1 or 2. For stocks, Wave 3 is usually the longest and most tradeable wave in the Elliott Wave cycle.
The Wave 3 target price is determined using Fibonacci ratios and should typically be 1.618 or more times the movement of Wave 1."
Still trying to figure out what happened today...
I posted a bit of DD on Reddit earlier today and looks like that brought in some interest. Go $OWCP! Welcome new shareholders! It's going to be an exciting few months!!!
No idea WTF is going on. Latest filing was on the 6th and shows RHO Capital Partners Inc taking a whopping 11.25% stake in the company as of Dec 30th. Over 3 million shares.
Revenue from the consulting contracts, the sale of skin cremes, and licensing of the sublingual tablet will put us in Dollarville. $2-7, IMHO, easy.
Starting Phase 1 FDA trials for psoriasis creme, skin cancer creme, Multiple Myeloma sublingual tablet, and/or PTSD sublingual tablet will, IMHO, put us above $10.
Once those trials go well and we start Phase 2 FDA trials, I'm thinking $20+.
By then the pro analysts will have initiated coverage and there we be a share price consensus. Institutional owners will step up and how high it can go is anyone's guess.
Old $OWCP articles, but reposting for any new folks:
http://ireadculture.com/blending-the-private-and-public-to-advance-cannabis-use/
https://www.greenprophet.com/2015/01/dr-cannabis-alan-shackelford-puts-medicine-into-cannabis-in-israel/
I've been to those types of conferences in Palm Beach. Been there. Done that.
I didn't reach out to Jason, but there is someone on here that's going to the conference who will be updating us in real time.
My take is that OWCP has signed a MMJ consulting contract with Florida and this conference is just another way for OWCP to raise awareness with the deep-pocketed investors in FL.
Final IRB safety and efficacy results will drop very soon. Selling now is insanity.
Once we have those final approvals things are going to get interesting very quickly! Cremes will be sold in EU, Asia, Canada, and in MMJ States. OWCP will put the incoming revenue to work immediately, firing up work on additional revenue pipelines.
News about licensing agreements can drop at any time.
News about the 3 State consulting contacts can drop at any time.
News about final patents on the delivery systems can drop at any time.
It's an exciting time to be an $OWCP shareholder!
And what do you predict the stock will do when they announce they've filed the IND?
Skin in the game prediction.
Once the psoriasis creme starts selling in Q2 and money starts pouring in, I predict OWCP will finally begin to pay themselves a decent salary. As you can see from the filings to date, they pay themselves each about $1,000 a month. Period.
Once revenue starts coming in, I fully expect to see some very well deserved raises. And I also fully expect to see some warrants/options issued, which will immediately be paid for with said new raises.
In Dishonest, Backstabbing America you'd be an idiot to not have an iron-clad contact with shares upfront. In Israel, we're talking about people who likely go to Temple together and, mark my words, once revenue starts pouring in they will be taking care of themselves for all the hard work and effort they have put into OWC.